Alliance for Pandemic Preparedness

April 8, 2021

Single Prime HAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] Phase 1b trials for a novel adenovirus-vector COVID-19 vaccine (hAd5-S-Fusion+N-ETSD developed by ImmunityBio) containing the SARS-CoV-2 antigen spike (S) and nucleocapsid (N) proteins demonstrated a 10-fold increase in mean S- and N-specific T-cell responses from patients (n=4) with prior SARS-CoV-2 infection after a single dose. For context, currently approved vaccines only target the S protein. Modeling predictions suggest that the elicited T-cell responses could be robust against the parent SARS-CoV-2 strain and variants of concern.

Sieling et al. (Apr 7, 2021). Single Prime HAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2. Pre-print downloaded Apr 8 from https://www.medrxiv.org/content/10.1101/2021.04.05.21254940v1